ORION ANNOUNCES the RAPID LEAD OPTIMIZATION of OB-004 – a CCR2 ANTAGONIST

Ottawa, Ontario, Canada, Nov. 30, 2021 (GLOBE NEWSWIRE) — Orion Biotechnology, a clinical stage company unlocking the therapeutic potential of  G Protein-Coupled Receptors (GPCRs) with a novel drug modality, proven discovery platform and best-in-class molecules, today announced the successful completion of its OB-004 lead optimization. OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor. The CCL2/CCR2 pathway plays an important role in oncology, inflammatory, metabolic, and neurological disorders. Read More